Global Colorectal Cancer (CRC) Diagnostics and Treatments Market to Hit USD16.89 Billion Mark by 2030

• Overview
• Table of Content
• Research Methodology
• Download Free Sample

The Global Colorectal Cancer (CRC) Diagnostics and Treatments Market size was valued at around USD10.89 Billion in 2024 and is projected to reach USD16.89 Billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 7.6% during the forecast period, i.e., 2025-30, cites MarkNtel Advisors in the recent research report.

Multiple factors are driving the market growth. The most important driver is the increasing prevalence of CRC globally. It creates a need for enhanced diagnosis and treatment modalities that drive growth. The speed of technological innovation in the diagnostics paradigm, including new AI-enabled imaging diagnostics, liquid biopsy, molecular diagnostics technologies, etc., is increasing earlier diagnosis and patient outcomes. Most country governments have also rolled out a CRC screening program at a national level to ensure that it is detected & cured in the early stages, which will also promote growth. Along with this, new access to public health campaigns for CRC screening and preventive care is leading to enhanced disease screening and navigating healthier lifestyle experiences. Finally, growth in healthcare spending in both developed and emerging market economies will continue to provide even more opportunities for new investment and new technologies in cancer research and therapeutics.

Several important trends are reshaping the market. The use of artificial intelligence and machine learning to improve the accuracy and reliability of diagnostic assessments is reshaping the landscape of colorectal cancer identification. Personalized medicine, through individualized genomic profiling, is motivating the development of targeted therapies that maximize clinical benefit for the patient. Noninvasive testing is growing in recognition because it is less invasive and more convenient for the patient undergoing the assessment. The use of multiomics approaches is also enhancing the discovery of CRC development and providing more precision in treatment regimens.

The market presents several attractive growth possibilities. Emerging market economies are considered strong opportunities for market development, primarily due to their expanding healthcare infrastructure and increased awareness of CRC screening. With the introduction of new therapy options within immunotherapy and precision medicine specifically, there are expanding options for the effectiveness of treatment. Furthermore, the increased availability of home testing kits increases screening convenience and accessibility for patients and subsequent utilization.

The market still has some hurdles to overcome that can hamper its growth. The high cost of new diagnostic equipment and therapies is a key barrier to access for many patients globally, especially in low- and middle-income countries. Furthermore, in the Global South, there are few screening centers and available health infrastructures that complicate early diagnosis. Moreover, new diagnoses and therapeutics are not available due to regulatory obstacles or prolonged approval processes to intervene with new diagnostics and therapeutics that may have transformed treatment. To further complicate care, some treatments for CRC come with toxic side effects, and resistance may occur for some of the treatments over time, making treatment difficult. Disparities in healthcare and differences in access to advanced medical centers will only serve to enlarge the time in which someone is diagnosed and treated, further states the research report, “Global Colorectal Cancer (CRC) Diagnostics and Treatments Analysis, 2025.”

Colorectal Cancer (CRC) Diagnostics and Treatments Market Segmentation Analysis

Hospitals Grab the Majority Market Share

Based on the End-User, the market is further bifurcated into Hospitals, Specialty Clinics, and others. Hospitals hold the majority share of the Global Colorectal Cancer (CRC) Diagnostics and Treatments, approximately 42% of the total market. The advancement is supported by the advanced diagnostic centers of hospitals. The availability of specialized gastroenterology laboratories, radiology suites, and oncology departments provides the capability for early and correct diagnosis of colorectal cancer. Colorectal cancer screening programs sponsored by various governments the world over, especially in developed economies, occur primarily in hospitals. This again sustains their role of early diagnosis.

Hospitals also provide integrated care functions that facilitate movement from screening to diagnosis to treatment. As a result, hospitals are the most desirable option for patients. Hospitals are constantly boosting their market position due to their ability to provide multidisciplinary care, the most innovative therapies, and involvement in clinical trials. This continues their dominant position in the CRC treatment and diagnostic market.

North America Leads the Colorectal Cancer (CRC) Diagnostics and Treatments Industry

North America dominates the global market. It holds approx. 40% of the total market value. The development of the sector is driven by an existing healthcare system with sophisticated medical technology that enables early and accurate diagnosis. The high prevalence of colorectal cancer in the Geocradle region is a reflection of the necessity for diagnostic and treatment strategies. Improved detection at an early stage and improved survival among patients are core elements of public health interventions, such as a national screening program and awareness programs. In addition, the presence of major biotech and pharmaceutical companies promotes an overall ecosystem of continued research which leads to new and improved treatments and diagnostic tools for colorectal cancer. When taken as a whole, these factors will keep North America as the leading global market for colorectal cancer diagnosis and treatment.

Competitive Landscape

With strategic initiatives such as mergers, collaborations, and acquisitions, the leading market companies, including Abbott Laboratories, Amgen Inc., Bayer AG, Bristol Myers Squibb, Eli Lilly and Company, GlaxoSmithKline PLC, F. Hoffmann-La Roche AG, Merck & Co., Inc., Novartis International AG, Pfizer Inc., and others are looking forward to strengthening their market positions.

Key Questions Answered in the Research Report                                                                                                       

1. What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
2. What are the trends influencing the current scenario of the market?
3. What key factors would propel and impede the industry across the globe?
4. How has the industry been evolving in terms of geography & product adoption?
5. How has the competition been shaping up across various regions?
6. How have buying behavior, customer inclination, and expectations from product manufacturers been evolving during 2020-30?
7. Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?